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1  | INTRODUC TION
Surgical operations exert considerable physical stress on patients 
perioperatively, and recent studies demonstrated that hyper-
glycemia exacerbates the inflammatory response and leads to 
oxidative stress, poor immune function, and endothelial dysfunc-
tion.1,2 Hyperglycemia is a risk factor for infectious diseases and 
results in increased comorbidities and mortality, and maintenance 
of blood glucose levels at <180 mg/dL has been recommended.3 
A previous retrospective study reported that in a comparison of 
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Aim: Pancreatectomy causes both hyperglycemia, secondary to surgical stress, and 
pancreatic diabetes, which leads to difficult-to-control postoperative blood glucose 
levels. We investigated whether using an artificial pancreas perioperatively to pro-
vide appropriate blood glucose control could reduce postoperative complications fol-
lowing pancreatectomy.
Methods: We retrospectively enrolled 52 patients who underwent pancreatectomy 
at Tokushima University Hospital from 2015 to 2019. The most recent 26/52 pa-
tients received perioperative blood glucose control using an artificial pancreas. 
Postoperative blood glucose control with manual insulin injections based on a sliding 
scale was performed in the earlier 26 patients (controls). We compared surgical out-
comes between the artificial pancreas group and the control group.
Results: There was no significant difference in patients' white blood cell or neutro-
phil counts, prognostic nutritional index, neutrophil-lymphocyte ratio, and C-reactive 
protein-to-albumin ratio on postoperative day 1; however, lymphocyte counts were 
higher in the artificial pancreas group. The number of serious complications of Clavien-
Dindo grade >IIIa was significantly lower in the artificial pancreas group (P < .05).
Conclusions: Using an artificial pancreas for perioperative blood glucose control in 
patients undergoing pancreatectomy decreased the number of serious complications 
through proper management of blood glucose levels without hypoglycemia, and may 
influence peripheral lymphocytes.
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intensive care patients in survival and nonsurvival groups, the 
survival group demonstrated significantly less blood glucose level 
variability.4 In 2003, a randomized controlled trial indicated that 
strict control of blood glucose with insulin in a surgical intensive 
care unit reduced postoperative morbidity and mortality, and 
that subsequent organ failure could be ameliorated and survival 
rates improved by maintaining blood glucose levels between 80 
and 110 mg/dL.5 However, studies also reported that intensive 
insulin therapy (IIT) was associated with hypoglycemic attacks6 
and that hypoglycemia with blood glucose levels < 40 mg/dL or 
levels of 70 mg/dL associated with conventional glycemic control 
methods, such as tight glycemic control with an open-loop sys-
tem and the sliding-scale method, can cause fatal complications 
in the presence of neurological disorders.7 Therefore, blood glu-
cose management by closed-loop systems is currently attracting 
attention.
An artificial pancreas has recently been developed that stabilizes 
glucose levels by continuously administering insulin and monitoring 
blood glucose. One study reported that glucose control using an arti-
ficial pancreas was stricter than that using the sliding scale method.8 
Perioperative tight glycemic control using a bedside artificial pan-
creas with a closed-loop system has also been proven safe and effec-
tive for avoiding hypoglycemia as well as for reducing blood glucose 
level variability, and resulted in good surgical outcomes.9 The use of 
an artificial pancreas for perioperative blood glucose management in 
a patient with glycogen storage disease or critically ill patients, such 
as those with severe burns, was beneficial in managing blood glucose 
levels without hypoglycemia.10,11
In hepatobiliary pancreatic surgery, diabetes associated with 
pancreatectomy is termed pancreatogenic diabetes. This complica-
tion necessitates high amounts of insulin and is associated with dif-
ficult-to-control postoperative blood glucose levels after pancreatic 
surgery.12,13 Furthermore, the surgery itself is invasive and the inci-
dence of complications is high.14 In this study, we evaluated whether 
using an artificial pancreas could reduce postoperative complica-
tions following pancreatectomy.
2  | MATERIAL S AND METHODS
2.1 | Patients and methods
This study was performed in accordance with the Helsinki 
Declaration of the World Medical Association. Our hospital 
introduced the use of an artificial pancreas in hepato-biliary-
pancreatic surgeries in 2019. This retrospective study enrolled 
52 patients who underwent pancreatectomy at Tokushima 
University Hospital from 2015 to 2019. All patients provided writ-
ten informed consent, and the study protocol was approved by 
the institutional review board of Tokushima University Hospital 
(approval number from the Tokushima Clinical Trial Management 
System [ToCMS]: 3215). Of the 52 patients, perioperative blood 
glucose control using an artificial pancreas was performed in 26 
patients since 2019 (artificial pancreas group). Postoperative 
blood glucose control with manual insulin injections based on 
commonly used sliding scales was performed in the previous 26 
patients (control group).
Glucose concentrations were controlled with a programmed 
infusion of insulin determined by the control algorithm of the 
STG-55 artificial pancreas (Nikkiso Inc) in the artificial pancreas 
group. The target blood glucose level was 120-180 mg/dL. Strict 
blood glucose control using the artificial pancreas was performed 
from the beginning of the operation to the next morning in the 
intensive care unit. Thereafter, the same postoperative manage-
ment was performed for both groups, according to the clinical 
guidelines of our hospital.
In all cases, intravenous hyperalimentation (IVH) was used imme-
diately after surgery, and cefmetazole was used as the antibacterial 
drug according to the clinical path.
2.2 | Parameters
We recorded the following patient clinicopathological data: age, sex, 
body mass index, diabetes mellitus, hemoglobin A1c, postoperative 
weight loss, white blood cell count and its fraction on postopera-
tive day 1, prognostic nutritional index (PNI), neutrophil-lymphocyte 
ratio (NLR), C-reactive protein to albumin ratio (CAR), and postop-
erative complications.
2.3 | Statistical analysis
Univariate analysis of the differences between the groups was de-
termined by log-rank tests, and multivariate analysis by chi-squared 
tests. All statistical analyses were performed using JMP version 13.0 




Table 1 shows the pancreatic disease and surgical procedures of 
the patients who underwent pancreatectomy in this study. The 52 
patients constituted 28 men and 10 women with an average age of 
63.6 ± 1.9 years (range, 33-84 years). Twenty-four patients (46%) 
were diagnosed with type 2 diabetes mellitus before surgery. Of the 
26 patients managed with the artificial pancreas, 14 patients (53.8%) 
underwent subtotal stomach-preserving pancreaticoduodenectomy, 
10 (38.5%) underwent distal pancreatectomy, and one (3.8%) un-
derwent total pancreatectomy. Of the 26 patients treated with in-
sulin injections using a sliding scale, 13 patients (50.0%) underwent 
subtotal stomach-preserving pancreaticoduodenectomy, 10 (38.5%) 
underwent distal pancreatectomy, and two (7.7%) underwent total 
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pancreatectomy. There was no significant difference in the number 
of patients undergoing the different surgical procedures between the 
two groups.
3.2 | Blood glucose control in the intraoperative and 
perioperative period
Table 2 shows the intraoperative and perioperative blood glucose 
levels in the patients of both groups. In the artificial pancreas group, 
stable glycemic control was achieved within the target blood glu-
cose range with mean blood glucose levels of 144.3 ± 21.8 mg/dL. 
The average minimum blood glucose level was 98 ± 13.4 mg/dL, and 
no severe hypoglycemia was observed. The period of management 
using the artificial pancreas was 1361.2 ± 331.0 minutes. On the 
other hand, control group showed significantly higher blood glucose 
levels than the artificial pancreas group, both at the mean and at 
the highest and lowest value. More notably, there was significant 
hypoglycemia of under 60 mg/dL in control group, and it is possible 
that there was actually more severe hypoglycemia.
3.3 | Preoperative patient backgrounds
Table 3 shows the preoperative backgrounds of the patients and 
postoperative outcomes. There was no significant difference in the 
patients' preoperative backgrounds between the control group and 
the artificial pancreas group, and type 2 diabetes mellitus (DM) was 
observed in 11 and 13 patients (42% and 50%), respectively. There 
were no differences of preoperative insulin dose in DM patients, 
blood cell count, and CRP level between two groups.
3.4 | Postoperative outcomes
There was no significant difference in patients' white blood cell and 
neutrophil counts on postoperative day 1, but lymphocyte counts were 
higher in the artificial pancreas group (P < .05) (Figure 1). Regarding 
the nutritional evaluation indices, there was no significant difference 
for PNI, NLR, and CAR. Regarding postoperative complications, the 
number of serious complications Clavien-Dindo grade (CD) >IIIa was 
significantly lower in the artificial pancreas group (P < .05) (Figure 2A); 
however, there was no significant difference in the length of hospital 
stay after surgery (Figure 2B). In the control group, CD III or higher 
complications included six cases of postoperative pancreatic fistula 
(POPF), one case of biliary fistula, and one case of intraperitoneal 
hemorrhage from the mesenteric artery and this patient needed open 
hemostasis. In the artificial pancreas group, CD IIIa complications were 
two cases of POPF and no patient suffered CD IIIb or higher compli-
cations. All patients with CD IIIa complications required either drain 
replacement or insertion. The mortality rate was 0% in both groups.
4  | DISCUSSION
Hyperglycemia induced by surgical stress often dysregulates liver 
metabolism and immune function, resulting in impaired postopera-
tive recovery.12 Moreover, perioperative hyperglycemia also plays 
a significant role in the development of postoperative infection.15 
As a countermeasure, IIT is performed for critically ill patients, and 
its specific aims are multiple organ protection and the prevention 
TA B L E  1   Pancreatic disease and surgical procedures performed 









Pancreatic cancer 40 23 17
Biliary cancer 6 2 4
IPMN 4 1 3
MCN 1 0 1
SCN 1 0 1
Procedures
SSPPD 27 13 14
DP 20 10 10







Abbreviations: DP, distal pancreatectomy; IPMN, intraductal 
papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; 
SCN, serous cystic neoplasm; SSPPD, subtotal stomach-preserving 
pancreaticoduodenectomy; TP, total pancreatectomy.
TA B L E  2   Perioperative blood glucose changes in patients with or without artificial pancreas
Blood glucose (mg/dL) Control (n = 26) Artificial Pancreas (n = 26) P value
Averagea  184.2 ± 28.2 (129.6-240.8) 144.3 ± 21.8 (85.1-167.5) <.001
Maximumb  258.5 ± 47.3 (182.0-361.0) 233.8 ± 23.0 (181.5-284.1) .021
Minimumc  117.8 ± 22.5 (58.0-170.0) 98.2 ± 13.4 (72.4-126.5) <.001
aAverage of the blood glucose level from the beginning of the operation to the next morning in the intensive care unit (perioperative period). 
bMaximum values of blood glucose in perioperative period. 
cMinimum values of blood glucose in perioperative period. Each data showed average ± standard deviation (minimum – maximum value). 
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and treatment of infection by normalizing and maintaining blood 
glucose concentrations at normal levels.16 However, it is unclear 
how soon blood glucose falls after insulin administration, and it has 
recently become clear that hypoglycemia has a greater prognostic 
effect.15 To address the problem of hypoglycemia, an artificial pan-
creas has recently been developed that stabilizes glucose levels by 
continuously administering insulin and monitoring blood glucose.1 
Using this system, strict glycemic control approaching normogly-
cemia was achieved, such as targeting blood glucose in the range 
of 80-110 mg/dL, without hypoglycemia, and with less variability 
in blood glucose concentration.7 A randomized clinical trial showed 
that tight perioperative glycemic control using a closed-loop artifi-
cial pancreas system decreased the rate of surgical site infections 
(SSI) in patients who underwent pancreatectomy or hepatectomy.17
In our study, there was no significant difference in the rate 
of occurrence of SSI; however, although the number of patients 
in this study was relatively low, serious complications over CD 
IIIa were significantly reduced in the artificial pancreas group. 
According to the clinical path, the drain is removed by postoper-
ative day 7 without POPF, bile leakage or deep SSI. In this study, 
the overall incidence of POPF or biliary fistula did not change, 
however, the deep SSI of CDIIIa, which required drain replace-
ment, decreased in the artificial pancreas group. There were no 
significant differences in the nutritional evaluation indices PNI, 
NLR, and CAR; however, lymphocyte counts on postoperative 
day 1 were higher in the artificial pancreas group. Although 
there is no doubt that perioperative nutritional management 
is important in pancreatectomy,18 one study reported that nu-
tritional assessment scores do not contribute to mortality and 
morbidity.19 In contrast, lymphocyte counts often decrease 
after major surgical operations and are considered to reflect an 





Pancreas (n = 26)
P 
value
Age Mean 66.2 ± 7.3 71.2 ± 10.4 .073
Sex M/ F 14/ 12 13/ 13 .781
BMI Mean 20.7 ± 3.1 22.5 ± 2.9 .043
DM -/ + 15/ 11 13/ 13 .578
HbA1c Mean 6.27 ± 1.13 6.68 ± 1.91 .363
Pancreatic hardness Soft/ Hard 18/ 6 18/ 6 1
Pancreatic duct diameter 
(mm)
Mean 5.04 ± 0.66 3.92 ± 0.32 .136
Post-operative data of day 1
WBC <15 000/≥15 000 8/ 18 12/14 .254
Neutro <15 000/≥15 000 5/ 5 12/9 .709
Lymph <500/≥500 6/ 4 4/17 .023
Alb <2.5/≥2.5 13/13 12/14 .781
CRP <10/≥10 12/14 9/17 .397
PNI <30/≥30 7/3 17/ 9 .793
NLR <20/≥20 4/6 12/10 .447
CAR <5/≥5 14/12 15/11 .780
Post-operative 
complications
-/+ 9/17 15/11 .095
CD≥IIIa -/+ 18/8 24/2 .035
SSI -/+ 25/1 25/1 1.000
POPF -/+ 17/9 21/5 .211
Bil. fistula -/+ 24/2 26/0 .149
Chylorrhea -/+ 23/3 26/0 .074
Post-operative weight loss <15%/≥15% 22/4 23/1 .187
Post-operative hospital 
stay (days)
Mean 25.1 ± 9.9 21.9 ± 10.6 .272
Abbreviations: Alb, albumin; Bil., biliary; BMI, body mass index; CAR, C-reactive protein-to-
albumin ratio; CD, Clavien–Dindo classification; CRP, C-reactive protein; DM, diabetes mellitus; 
HbA1c, hemoglobin A1c; Lymph, lymphocyte count; Neutro, neutrophil count; NLR, neutrophil–
lymphocyte ratio; PNI, prognostic nutritional index; POPF, Postoperative pancreatic fistula; SSI, 
surgical site infection; WBC, white blood cell.
TA B L E  3   A comparison of the 
characteristics and data from patients in 
the control and artificial pancreas groups 
undergoing pancreatectomy
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number of lymphocytes decreased significantly only 2 hours 
after transient hyperglycemia.21 In addition, it is reported that 
there is a correlation between postoperative lymphocyte count 
reduction and the incidence of postoperative pneumonia after 
surgery for lung cancer.22 We also reported that lymphocyte 
counts decreased early after surgery in liver transplant donors, 
and the subsequent increase in the regulatory T-cell population 
correlated with the rate of lethal complications.23 Therefore, 
even if the use of artificial pancreas is limited within 24 hours, it 
may contribute to the reduction of perioperative complications 
such as deep SSI following the lymphocyte count reduction. A 
previous study showed that IIT using an artificial pancreas re-
duced serum cytokine levels and the rate of surgical site infec-
tions,1 suggesting that the use of an artificial pancreas could 
suppress lymphocyte depletion and maintain immune function, 
resulting in the suppression of severe complications, which is 
consistent with our results. Furthermore, by suppressing blood 
glucose fluctuations, none of our patients under the control of 
an artificial pancreas experienced complications secondary to 
hypoglycemia.
The limitation of this study was the small number of patients 
and the lack of investigation of inflammation-related factors such as 
serum cytokine levels. Therefore, the causal relationship between 
suppression of lymphopenia and reduction of complications remains 
unclear. Based on the results of this study, we will continue to ac-
cumulate the number of cases and investigate these parameters to 
elucidate the mechanism.
In conclusion, the use of an artificial pancreas for periopera-
tive blood glucose control in pancreatectomy maintained lympho-
cyte counts and decreased the number of serious complications 
through proper management of blood glucose levels, without 
hypoglycemia.
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F I G U R E  1   Change in blood count before and after surgery. There was no significant difference in white blood cell and neutrophil counts 
on postoperative day 1. Lymphocyte counts were higher in the artificial pancreas group
F I G U R E  2   Postoperative outcomes. 
A, The number of serious complications > 
Clavien–Dindo grade IIIa was significantly 
lower in the artificial pancreas group. B, 
There was no significant difference in the 
length of hospital stay after surgery
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